KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash from Operations: 2011-2025

Historic Cash from Operations for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -$61.7 million.

  • Supernus Pharmaceuticals' Cash from Operations fell 215.22% to -$61.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.9 million, marking a year-over-year decrease of 58.33%. This contributed to the annual value of $172.0 million for FY2024, which is 54.79% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Cash from Operations of -$61.7 million as of Q3 2025, which was down 205.35% from $58.5 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Cash from Operations registered a high of $71.1 million during Q2 2022, and its lowest value of -$61.7 million during Q3 2025.
  • Its 3-year average for Cash from Operations is $28.2 million, with a median of $38.4 million in 2024.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Cash from Operations soared by 1,041.93% in 2023, and later slumped by 215.22% in 2025.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Cash from Operations stood at $48.8 million in 2021, then plummeted by 43.47% to $27.6 million in 2022, then spiked by 63.10% to $45.0 million in 2023, then declined by 1.23% to $44.4 million in 2024, then plummeted by 215.22% to -$61.7 million in 2025.
  • Its Cash from Operations stands at -$61.7 million for Q3 2025, versus $58.5 million for Q2 2025 and $30.6 million for Q1 2025.